Diarrhea News and Research

Latest Diarrhea News and Research

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Patients who receive antibiotics while in hospital may benefit from probiotics, say researchers

Patients who receive antibiotics while in hospital may benefit from probiotics, say researchers

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Saint Louis University extends search for new medicines to treat childhood diarrhea

Saint Louis University extends search for new medicines to treat childhood diarrhea

Report highlights successes in improving maternal health, reducing child mortality

Report highlights successes in improving maternal health, reducing child mortality

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Astellas submits application for marketing approval of enzalutamide for prostate cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

GUVAX reports successful results in phase I study of oral, Escherichia coli diarrhea vaccine

GUVAX reports successful results in phase I study of oral, Escherichia coli diarrhea vaccine

IBD patients are at higher risk of melanoma, report researchers

IBD patients are at higher risk of melanoma, report researchers

Study: 3/4 women experience constipation and other bowel disorders during their pregnancies

Study: 3/4 women experience constipation and other bowel disorders during their pregnancies

Research explores pharmaceutical advances for IBS, hepatitis C

Research explores pharmaceutical advances for IBS, hepatitis C

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

Certain varieties of clay have ability to kill MRSA, says ASU researcher

Certain varieties of clay have ability to kill MRSA, says ASU researcher

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Tips to keep dog park visits safe, healthy for dogs and dog owners

Tips to keep dog park visits safe, healthy for dogs and dog owners

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.